Get the weekly "what changed" email
Plain-English updates on AI-designed drugs in human trials. Free, weekly.
Free, weekly, unsubscribe anytime. Form not showing? Sign up here.
| Company | Drug | Disease | Phase | Status | Last update | First in humans | AI | Source |
|---|---|---|---|---|---|---|---|---|
| Recursion | REC-994 | Cerebral cavernous malformation | Stopped Phase 2 (completed) | Discontinued (May 2025 pipeline cull) | 2026-10-22 | ~2022-03-17 src | AI-assisted | source |
| Generate:Biomedicines | GB-0895 / golukibart (anti-TSLP antibody) | Severe asthma | Phase 3 Phase 3 (SOLAIRIA-1/2) | Recruiting | 2026-10-22 | ~2023-12-12 src | AI-discovered | source |
| Generate:Biomedicines / Roswell Park | GB-5267 (IL-18-armored MUC16 CAR T-cell therapy) | Platinum-resistant ovarian cancer | Phase 1 Phase 1 | Recruiting; first patient dosed (announced Oct 1, 2026) | 2026-10-22 | 2026-10-01 Just started src | AI-discovered | source |
| BigHat Biosciences | BHB810 (CDH17-directed VHH-Fc antibody-drug conjugate) | Advanced gastric and gastroesophageal junction adenocarcinoma; other GI cancers | Phase 1/2 Phase 1/2 | Recruiting | 2026-10-20 | ~2026-07-16 New 2026 src | AI-discovered | source |
| Insilico Medicine | Rentosertib (ISM001-055 / INS018_055) | Idiopathic pulmonary fibrosis (IPF) | Phase 3 Phase 3 | Recruiting | 2026-10-13 | ~2021-11 src | AI-discovered | source |
| Generate:Biomedicines | GB-4362 (anti-MMAE payload-neutralizing antibody) | Advanced / metastatic urothelial cancer (given with enfortumab vedotin + pembrolizumab to reduce MMAE toxicity) | Phase 1 Phase 1 | Recruiting; FDA Fast Track (company) | 2026-10-13 | ~2026-06-08 New 2026 src | AI-discovered | source |
| Relay Therapeutics | RLY-2608 / zovegalisib (PI3Kα inhibitor) | PIK3CA-mutated HER2-negative breast cancer | Phase 3 Phase 3 (ReDiscover-2) | Recruiting | 2026-10-05 | ~2021-12-08 src | AI-assisted | source |
| Takeda (from Nimbus Therapeutics) | Zasocitinib / TAK-279 (TYK2 inhibitor) | Plaque psoriasis (NDA under FDA priority review, decision expected Q1 2027); psoriatic arthritis | Filed/Approved NDA filed (Phase 3 complete in psoriasis; Phase 3 ongoing in PsA) | FDA accepted NDA under Priority Review (Sept 14, 2026); also under EMA review (Takeda, Sept 30, 2026) | 2026-09-30 | ~2021-08-11 src | AI-assisted | source |
| Recursion | REC-7735 (PI3Kα H1047R inhibitor) | PIK3CA H1047R-mutant solid tumors | Phase 1/2 Phase 1/2 (ZINNIA) | Recruiting | 2026-09-29 | ~2026-09 Just started src | AI-discovered | source |
| Enveda | ENV-294 | Atopic dermatitis | Phase 2 Phase 2 (2a) | Recruiting | 2026-09-25 | ~2024-10 src | AI-discovered | source |
| Enveda | ENV-294 (asthma study) | Asthma | Phase 2 Phase 2 | Recruiting | 2026-09-24 | ~2024-10 src | AI-discovered | source |
| Insilico Medicine | ISM6331 (pan-TEAD inhibitor) | Malignant mesothelioma; metastatic solid tumors | Phase 1/2 Phase 1/2 | Recruiting; first-in-human data at ESMO Oct 25, 2026 (company: 40% ORR at 130 mg in mesothelioma, n=5; no DLTs) | 2026-09-16 | ~2024-12-27 src | AI-discovered | source |
| Iambic Therapeutics | IAM1363 (HER2 inhibitor) | HER2-altered solid tumors | Phase 1 Phase 1/1b | Recruiting; updated data at ESMO Oct 23, 2026 (company: 36% PR at ≥960 mg, 41% intracranial PR) | 2026-09-09 | ~2024-03-25 src | AI-discovered | source |
| Absci | ABS-201 (anti-PRLR antibody) | Androgenetic alopecia (hair loss) | Phase 1/2 Phase 1/2a (HEADLINE) | Recruiting | 2026-09-03 | ~2025-12-03 src | AI-discovered | source |
| Insilico Medicine | ISM3412 | Locally advanced / metastatic solid tumors | Phase 1/2 Phase 1/2 | Recruiting | 2026-09-01 | ~2025-04-25 src | AI-discovered | source |
| Recursion | REC-1245 (RBM39 degrader) | Solid tumors and lymphoma | Phase 1/2 Phase 1/2 | Recruiting; dose expansion at 45 mg QD selected (Oct 15, 2026) | 2026-08-20 | ~2024-11-21 src | AI-discovered | source |
| Recursion | REC-2282 | Neurofibromatosis type 2 | Stopped Phase 2/3 | Terminated | 2026-08-17 | ~2010-05-04 src | AI-assisted | source |
| Recursion (Exscientia) | REC-617 / GTAEXS617 (CDK7 inhibitor) | Advanced solid tumors (incl. ovarian, head & neck, pancreatic) | Phase 1/2 Phase 1/2 | Recruiting; Recursion seeking a partner (Oct 15, 2026) | 2026-08-13 | ~2023-07-06 src | AI-discovered | source |
| Recursion (Exscientia) | REC-3565 (MALT1 inhibitor) | Relapsed/refractory B-cell malignancies | Phase 1 Phase 1 | Recruiting; Recursion seeking a partner (Oct 15, 2026) | 2026-08-13 | 2025-04-08 src | AI-discovered | source |
| Enveda | ENV-294 (Phase 2b atopic dermatitis study) | Atopic dermatitis | Phase 2 Phase 2 (2b dose-ranging) | Recruiting | 2026-08-06 | ~2024-10 src | AI-discovered | source |
| Healx | HLX-1502 | Neurofibromatosis type 1 (plexiform neurofibromas) | Phase 2 Phase 2 (INSPIRE-NF1) | Recruiting | 2026-07-29 | ~2025-02-10 src | AI-discovered | source |
| Insilico Medicine | ISM8207 | Advanced solid tumors; relapsed/refractory B-cell lymphoma | Phase 1 Phase 1 | Recruiting | 2026-07-24 | ~2024-04-25 src | AI-discovered | source |
| Insilico Medicine | ISM5939 (ENPP1 inhibitor) | Advanced / metastatic solid tumors | Phase 1 Phase 1 | Not yet recruiting | 2026-07-23 | Not dosed yet planned 2026-12-30 | AI-discovered | source |
| Absci | ABS-101 (anti-TL1A antibody) | Inflammatory bowel disease | Phase 1 Phase 1 (healthy volunteers; enrolment complete) | Active, not recruiting; Absci will not develop further internally and will seek a partner (Nov 2025) | 2026-07-03 | 2025-05-12 src | AI-discovered | source |
| Insilico Medicine | ISM5411 (garutadustat) | Ulcerative colitis | Phase 2 Phase 2 | Recruiting | 2026-07-01 | ~2023-11-08 src | AI-discovered | source |
| Insilico Medicine | ISM8969 | Obesity / cardiovascular risk (healthy and obese volunteers) | Phase 1 Phase 1 | Recruiting | 2026-06-22 | ~2026-06-15 New 2026 src | AI-discovered | source |
| Recursion (Exscientia) | REC-4539 / EXS74539 (LSD1 inhibitor) | Solid tumors incl. small-cell lung cancer; AML | Phase 1 Phase 1 | Recruiting | 2026-06-10 | ~2026-04-13 New 2026 src | AI-discovered | source |
| Recursion | REC-4881 (MEK1/2 inhibitor) | Familial adenomatous polyposis (FAP) | Phase 2 Phase 2 (Ph1b/2 TUPELO) | Recruiting; Ph1b/2 data update Oct 15, 2026 (registrational trial targeted 2H27, pending FDA) | 2026-06-05 | ~2009-12 src | AI-assisted | source |
| XtalPi / Signet Therapeutics | SIGX1094R (FAK/SRC inhibitor) | Diffuse gastric cancer | Phase 1 Phase 1 | Recruiting | 2026-05-14 | ~2024-12-12 src | AI-assisted | source |
| Lantern Pharma | LP-184 | Advanced solid tumors (Phase 1b/2 in glioblastoma planned via Starlight) | Phase 1 Phase 1a completed; Phase 1/2 planned | Active, not recruiting | 2026-05-04 | ~2023-06-09 src | AI-assisted | source |
| Lantern Pharma | LP-300 | Non-small cell lung cancer | Phase 2 Phase 2 | Recruiting; Part 2 (EGFR L858R only, up to 8 cycles) opened in Taiwan (Oct 7, 2026) | 2026-05-04 | ~1998-03 src | AI-assisted | source |
| Schrödinger | SGR-1505 (MALT1 inhibitor) | B-cell lymphoma (non-Hodgkin) | Phase 1 Phase 1 | Recruiting | 2026-02-13 | ~2023-04-10 src | AI-assisted | source |
| XtalPi / PharmaEngine | PEP08 | Advanced solid tumors | Phase 1 Phase 1 | Recruiting | 2026-02-13 | ~2025-08-26 src | AI-assisted | source |
| MindRank | MDR-001 (oral small-molecule GLP-1 receptor agonist) | Obesity / overweight (Phase 3 MOBILE, China); type 2 diabetes also targeted | Phase 3 Phase 3 | Recruiting per company (first patient dosed Feb 25, 2026); registry still lists Not yet recruiting | 2025-12-22 | ~2023-06-09 src | AI-assisted | source |
| Verge Genomics | VRG50635 | Amyotrophic lateral sclerosis (ALS) | Stopped Phase 1 (Ph1b) | Terminated (sponsor: lack of risk-benefit data); Verge reports missed efficacy endpoint | 2025-12-15 | ~2024-01-15 src | AI-discovered | source |
| Schrödinger | SGR-2921 (CDC7 inhibitor) | Acute myeloid leukemia; high-risk MDS | Stopped Phase 1 | Terminated (two treatment-related deaths, Aug 2025) | 2025-09-22 | ~2023-09-27 src | AI-assisted | source |
| Insilico Medicine (licensed to Exelixis) | ISM3091 / XL309 (USP1 inhibitor) | Advanced solid tumors | Phase 1 Phase 1 | Recruiting | 2025-09-05 | ~2024-04-03 src | AI-discovered | source |
| Schrödinger | SGR-3515 | Advanced solid tumors | Phase 1 Phase 1 | Recruiting | 2025-08-01 | ~2024-06-18 src | AI-assisted | source |
| BenevolentAI | BEN-2293 (pan-Trk inhibitor) | Atopic dermatitis | Stopped Phase 1/2a (completed) | Missed endpoints Completed; missed efficacy endpoints (Apr 2023) | 2023-06-18 | ~2020-10-14 src | AI-discovered | source |
| Exscientia / Sumitomo Dainippon Pharma | DSP-1181 (5-HT1A agonist) | Obsessive-compulsive disorder | Stopped Phase 1 | Discontinued (Sumitomo ended development after Phase 1 missed expectations; exact date not confirmed from a primary document) | Not verified | ~2020-01 src | AI-discovered | source |
What does "AI-discovered" mean?
A (AI-discovered): the company or a peer-reviewed source says AI found the target or designed the molecule. B (AI-assisted): AI was one tool among others, such as physics simulation plus machine learning. Failed programs are shown too. Dates come from ClinicalTrials.gov or company announcements. Full definition. Not medical advice.